FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	DER LEG		(Middle)		<u>Di</u>	2. Issuer Name and Ticker or Trading Symbol     Dianthus Therapeutics, Inc. /DE/ [ DNTH ]      3. Date of Earliest Transaction (Month/Day/Year)     09/11/2023								eck all appli X Directo	tor er (give title		10% Ow Other (s below)	ner	
C/O DIANTHUS THERAPEUTICS, INC. 7 TIMES SQUARE, 43RD FLOOR					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person					
(Street) NEW Y	ORK N	<b>Y</b> :	10036		RI	Rule 10b5-1(c) Transaction Indication								Form filed by More than One Reporting Person					
(City)	(Si	,	(Zip)			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)			saction	ction 2A. Deemed Execution Date,			3. Transact	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)			ed (A) or	5. Amou Securitie Benefici Owned I	unt of 6 es 6 ially (Following (	Form	: Direct C Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
					tive Securities Acqui				v	Amount	(D)		(Instr. 3	ansaction(s) nstr. 3 and 4)					
		Т							uired, Dis s, options					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code (I 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownershi Form: y Direct (D) or Indirec (I) (Instr. 4	Ownership	Beneficial Ownership t (Instr. 4)	
			Code	v	(A)	(D)	Date Exercisable		piration ite	Title	Amount or Number of Shares								
Stock Option (Right to Buy)	\$11.2	09/11/2023			A		6,500		(1)	09	/10/2033	Common Stock	6,500	\$0.00	6,500		D		

## **Explanation of Responses:**

1. This option represents a right to purchase a total of 6,500 shares of the Issuer's common stock, which will vest in full on the date that is the earlier of (i) the Issuer's 2024 Annual Meeting of Stockholders and (ii) September 11, 2024, subject to the Reporting Person's continued service to the Issuer.

## Remarks:

/s/ Adam Veness, as attorneyin-fact for Leon O. Moulder Jr.

09/13/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.